Transdermal drug delivery systems (TDDS) are medicated adhesive bandages or patches that are applied to the skin and transfer a drug dose via the skin and into the bloodstream. This patch improves faster healing of body injuries, provides a continuous infusion of the drug throughout time, and increases the therapeutic effect of drugs by avoiding drug-related problems. This is a basic approach in which a patch is applied to a wounded body part, from which the medicine slowly penetrates the skin and heals the injury.
The benefits of a Transdermal Drug Delivery Systems Market include the fact that it is non-invasive, less painful for the patient, administers a complete dose, provides controlled plasma levels of potent drugs, allows for early termination of therapy if necessary, is a cost-effective treatment, and the bandage or patch can be removed. Liner, drug, adhesive, membrane, blacking, matrix filler, and permeation enhancer are the main components of TDDS. The single-layer drug in adhesive, multi-layer drug in adhesive, reservoir, vapor, and matrix are all examples of TDDS.
In the near future, Transdermal Drug Delivery Systems Market in transdermal medication delivery systems is expected to aid market expansion. Transdermal patch design modification, insertion of pressure-sensitive adhesives, and permeation enhancers are examples of advanced technology that improve drug diffusion and increase the ability to hold an excess amount of medicine.
The expansion of the transdermal drug delivery system market is likely to be aided by an increase in the number of surgical procedures performed around the world and an increase in the prevalence of cardiovascular illnesses.
Because of the rise in emergency medical cases and surgical operations, North America and the Asia Pacific are likely to lead the market for transdermal drug delivery systems. According to the World Health Organization (WHO), the total number of surgeries performed worldwide in 2012 was roughly 312.9 million. During the projected period, cardiovascular problems are expected to expand at an exponential rate, which can be ascribed to the increased use of transdermal medication delivery methods.
The key players in the transdermal drug delivery systems market are:
ALLERGAN, Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co., Inc., IBSA Institut Biochimique SA, Mylan N.V., Pfizer, Inc., TEH SENG Pharmaceutical Mfg. Co., Ltd., and Teikoku Seiyaku Co., Ltd., 3M Pharmaceuticals Inc., Actelion Pharmaceuticals Ltd., Bayer Crop Science Ltd., BioGel
0 Comments